Loading clinical trials...

Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging | Clinical Trials | Clareo Health

RECRUITINGNA

Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging

NCT06817733•Chinese PLA General Hospital

Summary

Objective of the Clinical Trial The objective of this clinical trial is to preliminarily assess the feasibility and safety of performing precise prostate thermal vapor ablation under MRI/TURS guidance. The primary questions it aims to address are: Can precise prostate thermal vapor ablation under MRI/TURS guidance effectively treat benign prostatic hyperplasia (BPH) and alleviate lower urinary tract symptoms (LUTS)? What safety issues may arise in participants after undergoing prostate thermal vapor ablation? Study Procedures Participants Preoperative Evaluation: Participants will undergo comprehensive preoperative assessments, including clinical examinations and laboratory tests. Procedure: Participants will receive precise prostate thermal vapor ablation under MRI/TURS guidance. Postoperative Follow-up: Regular follow-up to reassess prostate volume. Periodic completion of the International Prostate Symptom Score (IPSS) questionnaire. Regular measurement of maximum urinary flow rate (Qmax) and post-void residual urine volume (PVR). Research Team The research team will conduct precise prostate thermal vapor ablation under MRI/TURS guidance for the participants and manage their follow-up assessments.

Eligibility

Age

45 - 85 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Age 45-85 years;
•International Prostate Symptom Score (IPSS) ≥ 8, indicating moderate to severe Lower Urinary Tract Symptoms (LUTS) that significantly impact quality of life;
•Poor response to pharmacological treatment or refusal of pharmacological treatment;
•Prostate volume 30-80 mL;
•Maximum urinary flow rate (Qmax) \< 15 mL/s;
•Post-void residual urine volume (PVR) \< 300 mL;
•Willingness to provide informed consent and participate in postoperative follow-up.

Exclusion Criteria

•Prostate volume \< 30 mL or \> 80 mL;
•Severe urinary tract infection;
•Preoperative definitive diagnosis of prostate cancer;
•Known neurogenic bladder, detrusor muscle weakness, urethral stricture, or other non-BPH causes of urinary obstruction;
•Patients with prostatitis;
•History of invasive prostate interventions, such as radiofrequency ablation, laser therapy, or microwave treatment;
•Patients with severe cardiovascular disease, chronic obstructive pulmonary disease, severe diabetes, hepatic or renal dysfunction, or systemic bleeding disorders, as assessed by the investigator to be unsuitable for surgery.

Locations (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

February 15, 2025

Primary Completion Date

December 20, 2025

Completion Date

December 31, 2025

Last Updated

December 5, 2025

Enrollment

ESTIMATED participants

Conditions

Benign Prostatic Hyperplasia (BPH)

Interventions

Transurethral Thermal Vaporization of the Prostate

PROCEDURE

Contacts

Qing Yuan, Doctor of Medicine

CONTACT

8601018910980422 qyuanmd@outlook.com

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

NCT07016620

Benign Prostatic Hyperplasia (BPH)

View study

COMPLETEDNA

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02026908

Benign Prostatic Hyperplasia (BPH)

View study

COMPLETEDNA

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

NCT02505919

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging

Inclusion Criteria

Exclusion Criteria

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate

Study of Median Lobe Prostatic UroLift Procedure